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Background: Information about the interactions of single nucleotide polymorphisms (SNPs) and overweight/
obesity on serum lipid profiles is still scarce. The present study was undertaken to detect ten SNPs and their
interactions with overweight/obesity on serum lipid levels.
Methods: A total of 978 normal weight and 751 overweight/obese subjects of Bai Ku Yao were randomly selected
from our previous stratified randomized cluster samples. Normal weight, overweight and obesity were defined as a
body mass index (BMI) < 24, 24–28, and > 28 kg/m2; respectively. Serum total cholesterol (TC), triglyceride (TG),
high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein (Apo) A1
and ApoB levels were measured. Genotyping of ATP-binding cassette transporter A1 (ABCA-1) V825I, acyl-CoA:
cholesterol acyltransferase-1 (ACAT-1) rs1044925, low density lipoprotein receptor (LDL-R) AvaII, hepatic lipase gene
(LIPC) -250G>A, endothelial lipase gene (LIPG) 584C>T, methylenetetrahydrofolate reductase (MTHFR) 677C>T, the
E3 ubiquitin ligase myosin regulatory light chain-interacting protein (MYLIP) rs3757354, proprotein convertase
subtilisin-like kexin type 9 (PCSK9) E670G, peroxisome proliferator-activated receptor delta (PPARD) +294T>C, and
Scavenger receptor class B type 1 (SCARB1) rs5888 was performed by polymerase chain reaction and restriction
fragment length polymorphism combined with gel electrophoresis, and then confirmed by direct sequencing. The
interactions were detected by factorial design covariance analysis.
Results: The genotypic and allelic frequencies of LIPC and PCSK9 were different between normal weight and
overweight/obese subjects, the genotypic frequency of LIPG and allelic frequency of MYLIP were also different
between normal weight and overweight/obese subjects (P < 0.05-0.001). The levels of TC, ApoA1 (ABCA-1); TC,
LDL-C, ApoA1, ApoB and ApoA1/ApoB (LIPC); TG, HDL-C, and ApoA1 (LIPG); TC, HDL-C, LDL-C, ApoA1 and ApoB
(MTHFR); HDL-C and ApoA1 (MYLIP) in normal weight subjects were different among the genotypes
(P < 0.01-0.001). The levels of LDL-C, ApoB and ApoA1/ApoB (ABCA-1); HDL-C, ApoA1, ApoB and ApoA1/ApoB
(LIPC); TC, HDL-C, ApoA1 and ApoB (LIPG); TC, TG, HDL-C, LDL-C, ApoA1 and ApoB (MTHFR); TC, TG and ApoB
(MYLIP); TG (PCSK9); TG, ApoA1 and ApoB (PPARD); and TC, HDL-C, LDL-C, ApoA1 and ApoB (SCARB1) in
overweight/obese subjects were different among the genotypes (P < 0.01-0.001). The SNPs of ABCA-1 (LDL-C and
ApoA1/ApoB); LIPC (TC, LDL-C, ApoA1 and ApoB); LIPG (ApoB); MTHFR (TC, TG and LDL-C); MYLIP (TC and TG);
PCSK9 (TG, HDL-C, ApoB and ApoA1/ApoB); PPARD (TG and ApoA1/ApoB); and SCARB1 (TG, ApoA1 and ApoB)
interacted with overweight/obesity to influence serum lipid levels (P < 0.05-0.001).
Conclusions: The differences in serum lipid levels between normal weight and overweight/obese subjects might
partly result from different genetic polymorphisms and the interactions between several SNPs and overweight/
obesity.
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Dyslipidemia such as elevated levels of total cholesterol
(TC) [1], triglyceride (TG) [2], low-density lipoprotein
cholesterol (LDL-C) [3], and apolipoprotein (Apo) B [4],
together with decreased levels of ApoA1 [4] and high-
density lipoprotein cholesterol (HDL-C) [5] has become
one of the most urgent public health problems in many
countries because of its high prevalence and a causal re-
lationship with serious medical condition such as coron-
ary artery disease (CAD), hypertension and stroke [6]. It
is well known that dyslipidemia is a complex trait caused
by multiple environmental and genetic factors and their
interactions [7-12]. The link between overweight/obesity
and dyslipidemia has been well documented [13-17].
Obesity is a specific phenotype that may be affected by
genetic and environmental factors, involving excessive
caloric intake, unhealthy lifestyle, insufficient physical
activity, social and economic forces, as well as metabolic
and endocrine abnormalities. The increase in body fat,
especially the intra-abdominal adipose tissue is a major
contributor to the development of dyslipidemia, insulin
resistance, and hypertension and is associated with
chronic diseases such as type 2 diabetes, CAD, metabolic
syndrome, stroke, sleep disorders, osteoarthritis, and
increased incidence of certain forms of cancer [17]. The
prevalence of obesity has dramatically increased during
recent years in all parts of the world [18]. According to
the World Health Organization (WHO), more than 400
million adults were obese in 2005, and it is estimated
that more than 700 million adults will be obese by 2015
[19]. Moreover, the rates of increase and the overall
prevalence of obesity vary greatly across ethnic groups
[20]. Among Americans, data from the National Health
and Nutrition Examination Survey (NHANES) con-
ducted in 2007–2008 showed that adults of 32.8% of
non-Hispanic whites, 44.1% of non-Hispanic blacks, and
39.3% of Mexican-Americans were either overweight or
obese [21]. The prevalence of overweight and obesity in
Chinese was 24.1% and 2.8% in men and 26.1% and 5.0%
in women; respectively. The prevalence of central obesity
was 16.1% in men and 37.6% in women. The prevalences
of overweight, obesity, and central obesity were higher
among residents in northern China compared with their
counterparts in southern China and among those in
urban areas compared with those in rural areas [22].
Obesity has become a major clinical and public health
problem that threatens to overwhelm already extended
healthcare services in many countries. Genetic influ-
ences on lipid traits have been suggested by numerous
studies. Recent large-scale genome-wide association
studies in multiple populations have identified more
than 95 loci associated with serum lipid levels [23].
Common variants at these loci together explain < 10% of
variation in each lipid trait [24-26]. Rare variants withlarge individual effects may also contribute to the herit-
ability of lipid traits [26]. But the results of these associ-
ation studies conducted with blood lipid traits are
inconsistent in diverse racial/ethnic groups. A major rea-
son for inconsistency among studies may be different
environmental modifiers that interact with genes to in-
fluence serum lipid levels.
China is a multiethnic country with 56 ethnic groups.
Han nationality is the largest ethnic group, and Yao na-
tionality is the eleventh largest minority among the 55 mi-
nority groups according to the population size. Bai Ku Yao
(White-trouser Yao), an isolated subgroup of the Yao mi-
nority, is named so because all of men wear white knee-
length knickerbockers. The population size is about 30
000. Because of isolation from the other ethnic groups,
the special customs and cultures including their clothing,
intra-ethnic marriages, dietary patterns, and corn wine
and rum intakes are still completely preserved to the
present day. Thus, this ethnic subgroup is thought to
share the same ethnic ancestry and to possess a homoge-
neous genetic background. Bai Ku Yao has become a use-
ful subgroup for population genetic studies. In previous
epidemiological studies, we found that the prevalence of
dyslipidemia was lower in normal weight than in over-
weight/obese subjects [7-9]. We hypothesized that the dif-
ferences in serum lipid levels between normal weight and
overweight/obese subjects might partly result from differ-
ent interactions of some single nucleotide polymorphisms
(SNPs) and overweight/obesity in this population. There-
fore, the purpose of this study was to detect ten SNPs in
different genes and evaluate their interactions with over-
weight/obesity on serum lipid levels in the Guangxi Bai
Ku Yao population. The SNPs were selected according to
the previous findings of genome-wide association studies
[23-26] and bioinformatics functional assessment. Com-
putational analysis of ten SNPs ascribed potential func-
tional characteristics to each variant allele. In addition, the
ten SNPs selected for genotyping also based on the fre-
quency of Beijing Han population from the Human Gen-
ome Project Database. The heterozygosity values were
higher than 10% for the minor allele frequency. These
SNPs have been associated with serum lipid profiles in the
Bai Ku Yao population [27-35].
Methods
Study population
The study population consisted of 1729 unrelated parti-
cipants of Bai Ku Yao who reside in Lihu and Baxu vil-
lages in Nandan County, Guangxi Zhuang Autonomous
Region, People’s Republic of China. They were randomly
selected from our previous stratified randomized cluster
samples [7-9]. The age of the subjects ranged from 15 to
86 years, with an average age of 41.38 ± 14.71 years.
There were 978 normal weight subjects (490 males and
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men and 373 women). All of the subjects were rural
agricultural workers. The subjects had no evidence of
diseases related to atherosclerosis, CAD and diabetes.
The participants were not taking medications known to
affect serum lipid levels (lipid-lowering drugs such as
statins or fibrates, beta-blockers, diuretics, hormones, or
contraceptive drugs). The protocol was approved by the
Ethics Committee of the First Affiliated Hospital,
Guangxi Medical University. Written informed consent
was obtained from each participant.
Epidemiological survey
The survey was done according to standardized methods
[7-9]. Questionnaires were administered to assess demo-
graphic information, socioeconomic status, lifestyle fac-
tors, and medical and medication history. Blood pressure
was measured three times by a well trained physician
with the use of a standard mercury sphygmomanometer
while subjects were seated and had rested for 5 min. Sys-
tolic and diastolic blood pressure values were the mean
of three measurements. Systolic blood pressure was
determined by the first Korotkoff sound, and diastolic
blood pressure by the fifth Korotkoff sound. Pulse pres-
sure was calculated as the systolic minus the diastolic
blood pressure. Weight was measured with a beam bal-
ance and height with a fixed stadiometer. Subjects were
measured without shoes and in a minimum of clothing.
Body mass index (BMI) was calculated as weight in kilo-
grams divided by the square of height in meters. Waist
circumference was measured at the umbilicus.
Biochemical measurements
Fasting venous blood samples of 5 mL were obtained
from all subjects. A part of the sample (2 mL) was col-
lected into glass tubes and used to determine serum
lipid levels. Another part of the sample (3 mL) was
transferred to tubes with anticoagulate solution and used
to extract deoxyribonucleic acid (DNA). The levels of
TC, TG, HDL-C, and LDL-C in samples were deter-
mined by enzymatic methods. Serum ApoA1 and ApoB
levels were detected by the immunoturbidimetric im-
munoassay. All determinations were performed with an
autoanalyzer (Type 7170A; Hitachi Ltd., Tokyo, Japan)
in our Clinical Science Experiment Center [7-9].
Genetic analyses
Genomic DNA was extracted from the peripheral blood
leukocytes by the phenol-chloroform method as our previ-
ous reports [27-35]. Genotyping of ATP-binding cassette
transporter A1 (ABCA-1) V825I (rs2066715), acyl-CoA:
cholesterol acyltransferase-1 (ACAT-1) rs1044925, low
density lipoprotein receptor (LDL-R) AvaII, hepatic lipase
gene (LIPC) -250G>A (rs2070895), endothelial lipase gene(LIPG) 584C>T (rs2000813), methylenetetrahydrofolate
reductase (MTHFR) 677C>T (rs1801133), the E3 ubiqui-
tin ligase myosin regulatory light chain-interacting protein
(MYLIP, also known as IDOL) rs3757354, proprotein con-
vertase subtilisin-like kexin type 9 (PCSK9) E670G
(rs505151), peroxisome proliferator-activated receptor
delta (PPARD) +294T>C (rs2016520) and Scavenger re-
ceptor class B type 1 (SCARB1) rs5888 was performed
using polymerase chain reaction and restriction fragment
length polymorphism (PCR-RFLP). The sequences of the
forward and reverse primers and restriction ezyme used
for the genotyping of ten SNPs are list in Table 1. The
thermocycling protocol, the approach to electrophoresis,
and the procedures for quality control have been
described previously [27-35]. Genotypes were scored by
an experienced reader blinded to epidemiological data and
serum lipid levels.
DNA sequencing
Fifty-eight samples (each genotype in two; respectively)
detected by the PCR-RFLP were also confirmed by direct
sequencing. The PCR products were purified by low
melting point gel electrophoresis and phenol extraction,
and then the DNA sequences were analyzed in Shanghai
Sangon Biological Engineering Technology & Services
Co., Ltd., People’s Republic of China.
Diagnostic criteria
The normal values of serum TC, TG, HDL-C, LDL-C,
ApoA1, ApoB levels and the ratio of ApoA1 to ApoB in
our Clinical Science Experiment Center were 3.10-5.17,
0.56-1.70, 1.16-1.42, 2.70-3.10 mmol/L, 1.20-1.60, 0.80-
1.05 g/L, and 1.00-2.50; respectively. The individuals with
TC > 5.17 mmol/L and/or TG > 1.70 mmol/L were
defined as hyperlipidemic [7-9]. The diagnostic criteria of
overweight and obesity were according to the Coopera-
tive Meta-analysis Group of China Obesity Task Force.
Normal weight, overweight and obesity were defined as a
BMI < 24, 24–28, and > 28 kg/m2; respectively [14,36].
Statistical analysis
Data are presented as means ± SD for continuous vari-
ables and as frequencies or percentages for categorical
variables. Chi square tests were used to compare the dif-
ferences in percentages and to assess Hardy-Weinberg
expectations. Differences in mean values were assessed
using analysis of covariance (ANCOVA) and unpaired t
tests. Potential confounding factors were sex, age, educa-
tion level, physical activity, blood pressure, alcohol
consumption, and cigarette smoking. All significant asso-
ciations were further corrected for multiple tests by a per-
mutation test. The permutation test was conducted by
changing the orders of dependant variable randomly
against the genotypes (under the null hypothesis - no
Table 1 The sequences of forward (F) and reverse (R) primers and restriction enzymes for genotyping of the ten SNPs
SNP Primer sequence Restriction enzyme PCR product Allele
ABCA-1 V825I F: 50-GGTAGCCCACCACTCTCCCCTATAAAG-30 TagI 525 bp G
(rs2066715) R: 50-ATCAGCTGCCTGTCCTTGGACTA-30 A
ACAT-1 F: 50-TATATTAAGGGGATCAGAAGT-30 RsaI 389 bp A
(rs1044925) R: 50-CCACCTAAAAACATACTACC-30 C
LDL-R AvaII F: 50-GTCATCTTCCTTGCTGCCTGTTTAG-30 AvaII 228 bp A-
R: 50-GTTTCCACAAGGAGGTTTCAAGGTT-30 A+
LIPC -250G>A F: 50-GGCAAGGGCATCTTTGCTTC-30 DraI 411-bp G
(rs2070895) R: 50-GGTCGATTTACAGAAGTGCTTC-30 A
LIPG 584C>T F: 50-CATGAGCTGAGATTGTTGTCAGTGC-30 NdeI 254 bp C
(rs2000813) R: 50-CAGTCAACCACAACTACATTGGCGTCTTTCTCTCAT-30 T
MTHFR 677C>T F: 50-CAAAGGCCACCCCGAAGC-30 HinfI 254 bp C
(rs1801133) R: 50-AGGACGGTGCGGTGAGAGTG-30 T
MYLIP F: 50-ACAGAGCAAAAGACCCTGTCTC-30 HaeIII 387 bp G
(rs3757354) R: 50-AAAGAACTGTGTGTGGGAGGAT-30 T
PCSK9 E670G F: 50-CACGGTTGTGTCCCAAATGG-30 Eam 1104I 440 bp A
(rs505151) R: 50-GAGAGGGACAAGTCGGAACC-30 G
PPARD +294T>C F: 50-CATGGTATAGCACTGCAGGAA-30 BslI 269 bp T
(rs2016520) R: 50-CTTCCTCCTGTGGCTGCTC-30 C
SCARB1 F: 50-CCTTGTTTCTCTCCCATCCTCACTTCCTCGACGC-30 HinI1 218 bp C
(rs5888) R: 50-CACCACCCCAGCCCACAGCAGC-30 T
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This process was repeated 1000 times. The P values of
1000 permutations were sorted in a descending manner. If
the observed P value is less than or equal to the 950th P
value, the association was considered statistically signifi-
cant. The allelic and genotypic frequencies were calculated
from the observed genotypic counts. The interactions of
ten SNPs and overweight/obesity on serum lipid levels
were assessed by using a factorial design covariance ana-
lysis after controlling for potential confounders. Multiple
linear regression was used to ascertain the correlation be-
tween genotypes (ABCA-1: GG = 1, GA = 2, AA = 3;
ACAT-1: AA = 1, AC = 2, CC = 3; LDL-R: A-A- = 1, A-A+
= 2, A+A+ = 3; LIPC: GG = 1, GA = 2, AA = 3; LIPG: CC
= 1, CT = 2, TT = 3; MTHFR: CC = 1, CT = 2, TT = 3;
MYLIP: AA = 1, AG = 2, GG = 3; PCSK9: AA = 1, AG = 2;
PPARD: TT = 1, TC = 2, CC = 3; and SCARB1: CC = 1,
CT = 2, TT = 3) or alleles (the minor allele noncarrier = 1,
the minor allele carrier = 2) and serum lipid parameters in
the combined population of normal weight and over-
weight/obese subjects, normal weight subjects, and over-
weight/obese subjects; respectively.Results
General characteristics
Table 2 shows the general characteristics of the parti-
cipants. The levels of education, weight, BMI, waistcircumference, systolic blood pressure, diastolic blood
pressure, serum TC, TG, LDL-C, ApoA1, ApoB, and
the percentages of subjects who consumed alcohol
were higher in overweight/obese than in normal
weight subjects (P < 0.05-0.001), whereas the levels of
serum HDL-C, the ratio of ApoA1 to ApoB, and the
percentages of subjects who smoked cigarettes were
lower in overweight/obese than in normal weight sub-
jects (P < 0.01 for all). There were no significant dif-
ferences in the levels of mean age, height, pulse
pressure, and the ratio of male to female between the
overweight/obese and normal weight subjects (P >
0.05 for all).Electrophoresis and genotypes
The PCR products of ABCA-1, ACAT-1, LDL-R, LIPC,
LIPG, MTHFR, MYLIP, PCSK9, PPARD, and SCARB1
SNPs were 525-, 389-, 228-, 411-, 254-, 254-, 387-, 440-,
269- and 218-bp nucleotide sequences; respectively. The
genotypes identified were named according to the pres-
ence or absence of the enzyme restriction sites (Figure 1).
Lane M is 50- or 100-bp marker ladder. The genotypes of
the ten SNPs are as follows: ABCA1, GG (lanes 1 and 2,
525-bp), GA (lanes 3 and 4, 525-, 302- and 223-bp), and
AA genotypes (lanes 5 and 6, 302- and 223-bp); ACAT-1,
AA (lanes 1-3, 389-bp), AC (lanes 4 and 5, 389-, 279-
and 110-bp), and CC genotypes (lanes 6 and 7, 279- and
Table 2 The general characteristics and serum lipid levels between the subjects with normal weight and overweight/
obesity
Characteristics Normal weight Overweight/obesity t (χ2) P
Number 978 751 – –
Male/female 490/488 378/373 0.009 0.924
Age, years 41.48±16.21 41.25±12.50 0.332 0.740
Education level, years 3.71±3.89 4.71±4.49 −4.170 0.000
Height, cm 153.73±7.57 154.29±8.49 −1.461 0.144
Weight, kg 50.28±6.20 63.19±8.86 −34.042 0.000
Body mass index, kg/m2 21.23±1.68 26.48±2.59 −48.285 0.000
Waist circumference, cm 70.58±6.56 82.90±7.39 −30.766 0.000
Alcohol consumption, n (%) 373 (38.1) 362 (48.2) 23.034 0.000
Cigarette smoking, n (%) 305 (31.2) 178 (23.7) 15.036 0.001
Systolic blood pressure, mmHg 119.69±17.40 125.84±17.64 −7.242 0.000
Diastolic blood pressure, mmHg 75.11±9.98 80.57±11.13 −10.563 0.000
Pulse pressure, mmHg 44.60±12.87 45.36±12.11 −1.251 0.211
Total cholesterol, mmol/L 4.46±0.94 5.01±1.05 −11.325 0.000
Triglyceride, mmol/L 1.21±1.02 1.74±1.50 −8.837 0.000
HDL-C, mmol/L 1.80±0.47 1.73±0.41 3.099 0.002
LDL-C, mmol/L 2.52±0.73 2.96±0.85 −11.180 0.000
Apolipoprotein (Apo) A1, g/L 1.37±0.31 1.40±0.27 −2.009 0.045
ApoB, g/L 0.84±0.22 0.98±0.24 −12.466 0.000
ApoA1/ApoB 1.75±0.70 1.53±0.58 7.256 0.000
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
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(lanes 7-12, 228-, 141- and 87-bp), and A-A- genotypes
(lanes 13-15, 228-bp); LIPC, GG (lanes 1-3, 411-bp), GA
(lane 4, 411-, 301- and 110-bp), and AA genotypes (lanes
5-7, 301- and 110-bp); LIPG, PCR product of the sample
(lane 1, 254-bp), CC (lanes 2 and 3, 254-bp), CT (lanes 4
and 5, 254-, 217- and 37-bp), and TT genotypes (lanes 6
and 7, 217- and 37-bp); MTHFR, CC (lanes 1 and 2, 245-
bp), CT (lane 3 and 4, 245-, 173- and 72-bp), and TT gen-
otypes (lanes 5 and 6, 173- and 72-bp); MYLIP, AA (lanes
1 and 2, 387-bp), AG (lanes 3 and 4, 387-, 306- and 81-
bp), and GG genotypes (lanes 5 and 6, 306- and 81-bp);
PCSK9, PCR products of the samples (lanes 1 and 2, 440-
bp), AG (lanes 3 and 4, 440-, 290- and 150-bp), and AA
genotypes (lanes 5 and 6, 290- and 150-bp); PPARD, TT
(lanes 1 and 2, 269-bp), TC (lanes 3-5, 269-, 167- and 102-
bp), and CC genotypes (lanes 6 and 7, 167- and 102-bp);
and SCARB1, TT (lanes 1 and 2, 218-bp), CT (lanes 3 and
4, 218-, 187- and 31-bp), and CC genotypes (lanes 5 and
6, 187- and 31-bp). The 37-bp fragment of LIPG and 31-
bp fragment of SCARB1 were invisible in the gel owing to
their fast migration speed. The GG homozygous of the
PCSK9 E670G was not detected in our study population.
Nucleotide sequences
The genotypes detected by PCR-RFLP were also con-
firmed by direct sequencing (Figure 2).Genotypic and allelic frequencies
The genotypic and allelic frequencies of the SNPs be-
tween normal weight and overweight/obese subjects are
summarized in Table 3. The genotypic distribution of
ten SNPs was in Hardy-Weinberg equilibrium (P > 0.05
for all). The genotypic and allelic frequencies of LIPC
and PCSK9 were different between normal weight and
overweight/obese subjects, the overweight/obese sub-
jects had higher LIPC -250A and PCSK9 670A allele fre-
quencies than normal weight subjects (P < 0.05-0.001).
The genotypic frequency of LIPG and allelic frequency
of MYLIP were also different between normal weight
and overweight/obese subjects (P < 0.05 for each). There
were no significant differences in the genotypic and al-
lelic frequencies of the remaining SNPs between normal
weight and overweight/obese subjects (P < 0.05 for all).
The GG homozygous of the PCSK9 E670G was not
detected in our study population.
Genotypes and serum lipid levels
The association of genotypes and serum lipid para-
meters between normal weight and overweight/obese
subjects is shown in Figure 3. The levels of TC,
ApoA1 (ABCA-1); TC, LDL-C, ApoA1, ApoB and
ApoA1/ApoB (LIPC); TG, HDL-C, and ApoA1
(LIPG); TC, HDL-C, LDL-C, ApoA1 and ApoB
(MTHFR); HDL-C and ApoA1 (MYLIP) in normal
Figure 1 Genotyping of ten SNPs by polymerase chain reaction and restriction fragment length polymorphism. ABCA-1, ATP-binding
cassette transporter A1; ACAT-1, acyl-CoA:cholesterol acyltransferase-1; LDL-R, low density lipoprotein receptor; LIPC, hepatic lipase gene; LIPG,
endothelial lipase gene; MTHFR, methylenetetrahydrofolate reductase; MYLIP, the E3 ubiquitin ligase myosin regulatory light chain-interacting
protein. PCSK9, proprotein convertase subtilisin-like kexin type 9; PPARD, peroxisome proliferator-activated receptor delta; SCARB1, Scavenger
receptor class B type 1.
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(P < 0.01-0.001).
The levels of LDL-C, ApoB and ApoA1/ApoB (ABCA-
1); HDL-C, ApoA1, ApoB and ApoA1/ApoB (LIPC);
TC, HDL-C, ApoA1 and ApoB (LIPG); TC, TG, HDL-C,
LDL-C, ApoA1 and ApoB (MTHFR); TC, TG and ApoB
(MYLIP); TG (PCSK9); TG and ApoA1 and ApoB
(PPARD); and TC, HDL-C, LDL-C, ApoA1 and ApoB
(SCARB1) in overweight/obese subjects were different
among the genotypes (P < 0.01-0.001).
Interactions of the SNPs and overweight/obesity on
serum lipid levels
The interactions of ten SNPs and overweight/obesity on
serum lipid levels are given in Table 4. The SNPs of
ABCA-1 (LDL-C and ApoA1/ApoB); LIPC (TC, LDL-C,
ApoA1 and ApoB); LIPG (ApoB); MTHFR (TC, TG andLDL-C); MYLIP (TC and TG); PCSK9 (TG, HDL-C,
ApoB and ApoA1/ApoB); PPARD (TG and ApoA1/
ApoB); and SCARB1 (TG, ApoA1 and ApoB) were
shown interactions with overweight/obesity to influence
serum lipid levels (P < 0.05-0.001).Correlation between genotypes or alleles and serum lipid
parameters
The results of multiple linear regression analysis be-
tween genotypes or alleles and serum lipid parameters
are shown in Tables 5, 6, 7. Serum lipid levels were also
associated with the genotypes or alleles of several SNPs
in the combined population of normal weight and over-
weight/obese subjects (Table 5), normal weight subjects
(Table 6), and overweight/obese subjects (Table 7) ; re-
spectively (P < 0.05-0.001).
Figure 2 The parts of the nucleotide sequence of ten SNPs by direct sequencing. ABCA-1, ATP-binding cassette transporter A1; ACAT-1,
acyl-CoA:cholesterol acyltransferase-1; LDL-R, low density lipoprotein receptor; LIPC, hepatic lipase gene; LIPG, endothelial lipase gene; MTHFR,
methylenetetrahydrofolate reductase; MYLIP, the E3 ubiquitin ligase myosin regulatory light chain-interacting protein. PCSK9, proprotein
convertase subtilisin-like kexin type 9; PPARD, peroxisome proliferator-activated receptor delta; SCARB1, Scavenger receptor class B type 1.
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Table 3 The genotypic and allelic frequencies between the subjects with normal weight and overweight/obesity [n (%)]
SNP Genotype (Allele) Normal weight (n = 978) Overweight/obesity (n = 751) χ2 P
ABCA-1 V825I GG 326 (33.3) 269 (35.8)
(rs2066715) GA 480 (49.1) 334 (44.5)
AA 172 (17.6) 148 (19.7) 3.708 0.157
G 1132 (57.9) 872 (58.1)
A 824 (42.1) 630 (41.9) 0.012 0.914
ACAT-1 AA 662 (67.7) 527 (70.2)
(rs1044925) AC 279 (28.5) 205 (27.3)
CC 37 (3.8) 19 (2.5) 2.671 0.263
A 1603 (82.0) 1259 (83.8)
C 353 (18.0) 243 (16.2) 2.080 0.149
LDL-R AvaII A-A- 527 (53.9) 389 (51.8)
A-A+ 371 (37.9) 295 (39.3)
A+A+ 80 (8.2) 67 (8.9) 0.824 0.662
A- 1425 (72.9) 1073 (71.4)
A+ 531 (27.1) 429 (28.6) 0.848 0.357
LIPC -250G>A GG 480 (49.1) 233 (31.0)
(rs2070895) GA 425 (43.5) 432 (57.5)
AA 73 (7.5) 86 (11.5) 57.882 0.000
G 1385 (70.8) 898 (59.8)
A 571 (29.2) 604 (40.2) 45.999 0.000
LIPG 584C>T CC 454 (46.4) 308 (41.0)
(rs2000813) CT 477 (48.8) 412 (54.9)
TT 47 (4.8) 31 (4.1) 6.314 0.043
C 1385 (70.8) 1028 (68.4)
T 571 (29.2) 474 (31.6) 2.255 0.133
MTHFR 677C>T CC 471 (48.2) 354 (47.1)
(rs1801133) CT 441 (45.1) 341 (45.4)
TT 66 (6.7) 56 (7.5) 0.404 0.817
C 1383 (70.7) 1049 (69.8)
T 573 (29.3) 453 (30.2) 0.305 0.581
MYLIP AA 230 (23.5) 148 (19.7)
(rs3757354) AG 477 (48.8) 363 (48.3)
GG 271 (27.7) 240 (32.0) 5.431 0.066
A 937 (47.9) 659 (43.9)
G 1019 (52.1) 843 (56.1) 5.550 0.018
PCSK9 E670G AA 916 (93.7) 721 (96.0)
(rs505151) AG 62 (6.3) 30 (4.0)
GG 0 0 4.636 0.031
A 1894 (96.8) 1472 (98.0)
G 62 (3.2) 30 (2.0) 4.509 0.034
PPARD +294T>C TT 559 (57.2) 396 (52.7)
(rs2016520) TC 354 (36.2) 312 (41.5)
CC 65 (6.6) 43 (5.7) 5.239 0.073
T 1472 (75.3) 1104 (73.5)
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Table 3 The genotypic and allelic frequencies between the subjects with normal weight and overweight/obesity [n (%)]
(Continued)
C 484 (24.7) 398 (26.5) 1.375 0.241
SCARB1 CC 548 (56.0) 417 (55.5)
(rs5888) CT 390 (39.9) 311 (41.4)
TT 40 (4.1) 23 (3.1) 1.497 0.473
C 1486 (76.0) 1145 (76.2)
T 470 (24.0) 357 (23.8) 0.032 0.859
SNP, single nucleotide polymorphism; ABCA-1, ATP-binding cassette transporter A1; ACAT-1, acyl-CoA:cholesterol acyltransferase-1; LDL-R, low density lipoprotein
receptor; LIPC, hepatic lipase gene; LIPG, endothelial lipase gene; MTHFR, methylenetetrahydrofolate reductase; MYLIP, the E3 ubiquitin ligase myosin regulatory
light chain-interacting protein; PCSK9, proprotein convertase subtilisin-like kexin type 9; PPARD, peroxisome proliferator-activated receptor delta; SCARB1,
Scavenger receptor class B type 1.
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Serum lipid levels in the overweight/obese subjects
In the present study, we showed that the levels of serum
TC, TG, LDL-C, ApoA1, and ApoB were higher, and the
levels of serum HDL-C and the ratio of ApoA1 to ApoB
were lower in overweight/obese than in normal weight
subjects. This is in agreement with those of previous
studies [13-17]. Dyslipidemia in the obesity may be asso-
ciated with insulin resistance [37-40]. Insulin is a lipid-
synthetic hormone, thus alteration in a gene regulating
insulin gene transcription may alter lipid metabolism as
well and contribute to dyslipidemia. The liver is the
main target organ of the insulin effect. Insulin resistance
can descend the repression of insulin on the concentra-
tions of plasma free fatty acids, increase the plasma
levels of free fatty acids, promote free fatty acids into the
liver, and stimulate the synthesis and release of very low
density lipoprotein (VLDL) in the liver. At the same
time, insulin resistances can also decline the activity of
lipoprotein lipase (LPL), reduce the metabolism of
VLDL, and increase the levels of plasma VLDL.Genotypic and allelic frequencies in different populations
We showed that the genotypic and allelic frequencies of
LIPC -250G>A and PCSK9 E670G were different be-
tween normal weight and overweight/obese subjects, the
overweight/obese subjects had higher LIPC -250A and
PCSK9 670A allele frequencies than normal weight sub-
jects. The genotypic frequency of LIPG 584C>T and
allelic frequency of MYLIP rs3757354 were also different
between normal weight and overweight/obese subjects.
The allelic frequencies of LIPC -250G>A between
African Americans and white Americans were quite dif-
ferent in several previous studies: the less common allele
(−250A) of the LIPC polymorphisms in white Americans
was the more common allele in African Americans
[41,42]. The frequency of the LIPC -250A allele was
found to range between 15-21% among Caucasians [41],
32% among Brazilian [43], 39% among Taiwanese-
Chinese [44], 45-53% among African Americans [41,42]and 47% among Japanese-Americans [41]. The frequency
of PCSK9 670G allele was rare in whites but present in
approximately 24.8% of blacks [45]. Kotowski et al. [46]
also reported that the minor-allele frequency (670G) in
the Dallas Heart Study (DHS) was 3.6% in whites, 4.2%
in Hispanics, and 26.0% in blacks. The frequency of the
PCSK9 670G allele in patients selected from Universi-
tätsklinikum Hamburg-Eppendorf Martinistrasse, Ham-
burg, Germany was 5% [47] which lies between that
observed in the TexGen population, 4.4% and that
reported for the Lipoprotein Coronary Atherosclerosis
Study, 7.4% by Chen et al. [48] in their original study.
There was no significant difference in the frequency of
the PCSK9 670G allele in patients with LDL-C below
the 50th percentile for age and sex, 4.4%, those with
LDL-C between the 50th and 95th percentiles, 6.4% and
those with LDL-C above the 95th percentile, 6.4% [47].
The 670G carrier in Chinese Taiwanese was identified
less frequently in patients with CAD than in controls
(9.9% vs. 11.9%), but the difference was not significant
in a multivariable logistic regression analysis [49]. The
frequency of LIPG 584T allele was 10.3% in blacks,
31.2% in white controls, 32.6% in whites with high
HDL-C [50], 26% in the Lipoprotein and Coronary
Atherosclerosis Study population (white individuals,
but including 27 or 7% African Americans) [51], 26%
in Japanese [52], and 21.6% in healthy school-aged
Japanese children [53].Associations between SNPs and serum lipid levels
The potential associations between these lipid-related gene
SNPs and serum lipid levels [27-35] or obesity [54-65] in
humans have been evaluated in a large number of studies.
However, previous findings on the association of these
SNPs with the changes in serum lipid levels or obesity
(BMI) are inconsistent in different racial/ethnic groups.
ABCA1 R219K (rs2230806) was associated with altered
plasma HDL-C concentrations. This association on HDL-C
levels was modified by BMI in a Chinese population
from Chengdu area [54]. ABCA1 gene variant (R230C,
Figure 3 The genotypes of ten SNPs and serum lipid levels between normal weight and overweight/obese subjects. TC, total
cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoA1, apolipoprotein A1;
ApoB, apolipoprotein B; ApoA1/B, the ratio of apolipoprotein A1 to apolipoprotein B; ABCA-1, ATP-binding cassette transporter A1; ACAT-1, acyl-
CoA:cholesterol acyltransferase-1; LDL-R, low density lipoprotein receptor; LIPC, hepatic lipase gene; LIPG, endothelial lipase gene; MTHFR,
methylenetetrahydrofolate reductase; MYLIP, the E3 ubiquitin ligase myosin regulatory light chain-interacting protein; PCSK9, proprotein
convertase subtilisin-like kexin type 9; PPARD, peroxisome proliferator-activated receptor delta; SCARB1, Scavenger receptor class B type 1; aP <
0.01, bP < 0.005, and cP < 0.001 (after permutation correction).
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duals was also associated with low HDL-C levels, obesity
and type 2 diabetes in Mexican Mestizos. The 230C allele
was associated with lower HDL-C levels and with higher
BMI in the combined analysis of Native American popula-
tions [55]. Kitjaroentham et al. [56] showed that over-
weight/obese men carrying the mutant allele of ABCA1R219K had lower HDL-C levels than the controls. How-
ever, no positive association was observed using bivariate
logistic regression analysis. On the contrary, there was no
difference in HDL-C levels among genotypes in ABCA1
I883M (rs4149313) polymorphism. No difference was
detected in genotypic frequency between the overweight/
obese and control subjects for both polymorphisms. Two
Table 4 Interactions of several SNPs and overweight/obesity on serum lipid levels
SNP Genotype TC (mmol/L) TG (mmol/L) HDL-C (mmol/L) LDL-C (mmol/L) ApoA1 (g/L) ApoB (g/L) ApoA1/ ApoB
ABCA-1 V825I GG – – – – – – –
(rs2066715) GA – – – " – – #
AA – – – " – – #
F 1.473 2.937 1.717 3.687 1.913 2.941 6.485
P 0.230 0.053 0.180 0.005c 0.148 0.053 0.000c
ACAT-1 rs1044925 AA – – – – – – –
(rs1044925) AC – – – – – – –
CC – – – – – – –
F 0.475 1.457 0.341 0.320 1.635 1.071 1.944
P 0.622 0.233 0.711 0.726 0.195 0.343 0.143
LDL-R AvaII A-A- – – – – – – –
A-A+ – – – – – – –
A+A+ – – – – – – –
F 1.681 0.242 0.553 0.857 1.377 0.430 0.462
P 0.186 0.785 0.576 0.425 0.253 0.650 0.630
LIPC -250G>A GG " – – " – " –
(rs2070895) GA – – – – – " –
AA – – – – " – –
F 3.733 0.266 1.584 3.345 3.292 4.138 2.116
P 0.005c 0.766 0.205 0.007c 0.007c 0.003c 0.121
LIPG 584C>T CC – – – – – – –
(rs2000813) CT – – – – – – –
TT – – – – – " –
F 1.286 0.210 0.357 1.452 2.195 3.616 1.812
P 0.277 0.810 0.700 0.234 0.112 0.005c 0.164
MTHFR 677C>T CC – – – " – – –
(rs1801133) CT " – – – – – –
TT – " – # – – –
F 3.110 3.463 0.627 9.236 0.058 2.684 0.675
P 0.009c 0.006c 0.534 0.000c 0.944 0.069 0.509
MYLIP AA – – – – – – –
(rs3757354) AG " " – – – – –
GG – – – – – – –
F 6.864 4.325 1.818 2.495 0.684 1.895 1.388
P 0.000c 0.003c 0.307 0.083 0.505 0.151 0.250
PCSK9 E670G AA – – – – – – –
(rs505151) AG – " # – – " #
F 0.980 25.662 7.831 0.002 1.371 6.319 4.357
P 0.322 0.000c 0.001c 0.968 0.242 0.002c 0.007c
PPARD +294T>C TT – – – – – – –
(rs2016520) TC – " – – – – –
CC – – – – – – "
F 1.832 5.737 1.235 1.087 0.171 1.362 3.985
P 0.160 0.001c 0.291 0.337 0.843 0.257 0.004c
Yin et al. Cardiovascular Diabetology 2012, 11:123 Page 11 of 18
http://www.cardiab.com/content/11/1/123
Table 4 Interactions of several SNPs and overweight/obesity on serum lipid levels (Continued)
SCARB1 CC – – – – – " –
(rs5888) CT – – – – # – –
TT – " – – # – –
F 1.809 4.396 1.720 2.211 3.226 3.118 0.051
P 0.164 0.002c 0.179 0.110 0.008c 0.009c 0.778
SNP, single nucleotide polymorphism; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol;
ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; ApoA1/ApoB, the ratio of apolipoprotein A1 to apolipoprotein B; ABCA-1, ATP-binding cassette transporter A1;
ACAT-1, acyl-CoA:cholesterol acyltransferase-1; LDL-R, low density lipoprotein receptor; LIPC, hepatic lipase gene; LIPG, endothelial lipase gene; MTHFR,
methylenetetrahydrofolate reductase; MYLIP, the E3 ubiquitin ligase myosin regulatory light chain-interacting protein; PCSK9, proprotein convertase subtilisin-like
kexin type 9; PPARD, peroxisome proliferator-activated receptor delta; SCARB1, Scavenger receptor class B type 1; “C” is the P-value after permutation correction.
": genotype and overweight/obesity interactions to increase serum lipid levels; #: genotype and overweight/obesity interactions to decrease serum lipid levels; –:
no interaction of genotypes and overweight/obesity on serum lipid levels.
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LDL-R ApaLI and HincII polymorphisms were associated
with obesity in essential hypertensives but not in normo-
tensives [57,58]. Griffiths et al. [59] showed that LDL-R
microsatellite marker, located more towards the 30 end of
the gene, was associated with obesity in the normotensive
population studied. There was also a significant associ-
ation between variants of the LDL-R microsatellite and
obesity, in the overall tested population, due to a contrib-
uting effect in females, but not in males [60]. These results
indicate that LDL-R could play an important role in the
development of obesity, which might be independent of
hypertension or sex. MTHFR 677T allele was associated
with obesity, hypertriglyceridemia and low HDL-C levels
[61]. Birth weights were lower in 677TT than in 677CC
and 677CT subjects, as well as birth lengths [62]. In sub-
jects with and without type 2 diabetes, PPARD +294T>C
was associated with BMI, HDL-C, leptin, and TNF-alpha
and was dependent on gender [63]. BMI in metabolic syn-
drome patients with +294C allele carriers were signifi-
cantly higher than that of TT genotype [64]. However,
Aberle et al. [65] showed that the PPARD +294C allele
was significantly associated with a lower BMI. In this
study, we showed that the levels of TC, ApoA1 (ABCA-1);
TC, LDL-C, ApoA1, ApoB and ApoA1/ApoB (LIPC); TG,
HDL-C, and ApoA1 (LIPG); TC, HDL-C, LDL-C, ApoA1
and ApoB (MTHFR); HDL-C and ApoA1 (MYLIP) in nor-
mal weight subjects were different among the genotypes.
The levels of LDL-C, ApoB and ApoA1/ApoB (ABCA-1);
HDL-C, ApoA1, ApoB and ApoA1/ApoB (LIPC); TC,
HDL-C, ApoA1 and ApoB (LIPG); TC, TG, HDL-C, LDL-
C, ApoA1 and ApoB (MTHFR); TC, TG and ApoB
(MYLIP); TG (PCSK9); TG and ApoA1 and ApoB
(PPARD); and TC, HDL-C, LDL-C, ApoA1 and ApoB
(SCARB1) in overweight/obese subjects were also differ-
ent among the genotypes. Serum lipid levels were also
associated with the genotypes or alleles of several SNPs in
the combined population of normal weight and over-
weight/obese subjects, normal weight subjects, and over-
weight/obese subjects; respectively. These results suggest
that the associations of these SNPs and serum lipid levelsare different between normal weight and overweight/
obese subjects.
Interactions between SNPs and overweight/obesity on
serum lipid levels
The interactions of SNPs and overweight/obesity on
serum lipid parameters are limited. In an examination of
the effect of body fat on the genotypic effects in the chil-
dren, Talmud et al. [66] showed that there was significant
interaction between tertiles of sum of skinfold thickness
and the LIPC -480C>T genotype in determining HDL-C
levels. In the lowest tertile, carriers of the -480T allele had
lower mean HDL-C levels, whereas in the two upper ter-
tiles, -480T carriers had higher mean HDL-C levels when
compared with the CC homozygotes. In a previous study
[67], the interaction between BMI, the LIPC -514C>T
polymorphism, and hepatic lipase activity was examined
in white and African American men. The results showed
that increased BMI was associated with increased hepatic
lipase activity in men. A striking additive effect of BMI
and the LIPC -514C>T polymorphism on hepatic lipase
activity was observed. The joint effects of BMI and LIPC
-514C>T genotypes strongly influenced hepatic lipase ac-
tivity and were significantly greater than the effects of ei-
ther factor considered alone. LIPC -514C>T and LIPC
-250G>A SNPs have been demonstrated in complete link-
age disequilibrium [30]. There was evidence for an inter-
action of the LIPC promoter polymorphism with visceral
obesity in determining the level of hepatic lipase activity,
the presence of the LIPC -514T allele seems to attenuate
the increase in hepatic lipase activity with high levels of
intra-abdominal fat [68]. The interactions of LIPC
-514C>T and LIPC -250G>A SNPs and obesity on HDL-C
levels were also observed in Taiwanese-Chinese men but
not in women [44]. For males, significant interactions
were noted between the two studied polymorphisms and
obesity on HDL-C levels. For obese males, significantly
higher HDL-C levels were found for carriers of the -514T
and -250A alleles in comparison with non-carriers. In
contrast, no significant differences were found for non-
obese male subjects bearing different genotypes of the
Table 5 Correlation between genotypes or alleles and serum lipid levels in the total population
Lipid Genotype/allele Unstandardized coefficient Std. error Standardized coefficient t P
TC ACAT-1 rs1044925 genotype −0.099 0.043 −0.053 −2.287 0.022
LIPC -250G>A allele 0.101 0.046 0.050 2.170 0.030
LIPG 584C>T genotype 0.149 0.043 0.079 3.503 0.000
LIPG 584C>T allele 0.169 0.049 0.077 3.425 0.001
MTHFR 677C>T genotype 0.218 0.037 0.133 5.854 0.000
MTHFR 677C>T allele 0.269 0.046 0.133 5.841 0.000
PPARD +294T>C allele 0.147 0.050 0.068 2.963 0.003
TG MTHFR 677C>T genotype 0.146 0.054 0.062 2.701 0.007
MYLIP rs3757354 genotype −0.102 0.042 −0.057 −2.456 0.014
PPARD +294T>C allele 0.321 0.086 0.087 3.732 0.000
SCARB1 rs5888 genotype −0.041 0.023 −0.049 −2.039 0.042
HDL-C ACAT-1 rs1044925 genotype −0.057 0.022 −0.062 −2.643 0.008
ACAT-1 rs1044925 allele −0.051 0.025 −0.048 −2.024 0.043
LIPC -250G>A genotype 0.038 0.016 0.055 2.366 0.018
LIPG 584C>T genotype 0.086 0.018 0.108 4.667 0.000
LIPG 584C>T allele 0.080 0.021 0.087 3.762 0.000
MTHFR 677C>T genotype 0.097 0.017 0.132 5.718 0.000
MTHFR 677C>T allele 0.123 0.021 0.136 5.868 0.000
MYLIP rs3757354 genotype 0.036 0.015 0.058 2.465 0.014
LDL-C ABCA-1 V825I genotype 0.075 0.025 0.068 2.954 0.003
MTHFR 677C>T genotype 0.075 0.029 0.059 2.562 0.010
MTHFR 677C>T allele 0.120 0.036 0.077 3.334 0.001
ApoA1 ACAT-1 rs1044925 genotype −0.042 0.013 −0.074 −3.143 0.002
ACAT-1 rs1044925 allele −0.042 0.016 −0.063 −2.672 0.008
LIPC -250G>A genotype 0.036 0.012 0.068 3.020 0.003
LIPG 584C>T genotype 0.040 0.012 0.076 3.303 0.001
LIPG 584C>T allele 0.039 0.014 0.064 2.781 0.005
MTHFR 677C>T genotype 0.053 0.010 0.118 5.130 0.000
MTHFR 677C>T allele 0.068 0.013 0.123 5.338 0.000
ApoB MTHFR 677C>T genotype 0.032 0.008 0.086 3.781 0.000
MTHFR 677C>T allele 0.042 0.010 0.092 4.049 0.000
ApoA1/ApoB LIPC -250G>A genotype 0.070 0.026 0.063 2.649 0.008
TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoA1, apolipoprotein A1; ApoB,
apolipoprotein B; ApoA1/ApoB, the ratio of apolipoprotein A1 to apolipoprotein B; ABCA-1, ATP-binding cassette transporter A1; ACAT-1, acyl-CoA:cholesterol
acyltransferase-1; LDL-R, low density lipoprotein receptor; LIPC, hepatic lipase gene; LIPG, endothelial lipase gene; MTHFR, methylenetetrahydrofolate reductase;
MYLIP, the E3 ubiquitin ligase myosin regulatory light chain-interacting protein; PCSK9, proprotein convertase subtilisin-like kexin type 9; PPARD, peroxisome
proliferator-activated receptor delta; SCARB1, Scavenger receptor class B type 1.
Yin et al. Cardiovascular Diabetology 2012, 11:123 Page 13 of 18
http://www.cardiab.com/content/11/1/123LIPC -514C>T and -250G>A polymorphisms. For both
obese women and non-obese ones, no significant differ-
ence was detected between different genotypes of the two
studied polymorphisms and HDL-C levels [44]. The bene-
ficial effect of the LIPC -514T allele on plasma HDL2-C
levels was abolished in the presence of visceral obesity
[69]. Swarbrick et al. [70] reported that obese subjects car-
rying the Ala allele of the Pro12Ala polymorphism of the
PPAR-gamma2 gene, but not the non-obese analogs, had
a greater risk of developing combined hyperlipidemia and
low-HDL-C levels. In the current study, we provide im-
portant insights for the interactions of several SNPs andoverweight/obesity on serum lipid phenotypes. The SNPs
of ABCA-1 (LDL-C and ApoA1/ApoB); LIPC (TC, LDL-
C, ApoA1 and ApoB); LIPG (ApoB); MTHFR (TC, TG
and LDL-C); MYLIP (TC and TG); PCSK9 (TG, HDL-C,
ApoB and ApoA1/ApoB); PPARD (TG and ApoA1/
ApoB); and SCARB1 (TG, ApoA1 and ApoB) interacted
with overweight/obesity to modulate serum lipid levels.
These findings suggest that some serum lipid parameters
in our study subjects were partly influenced by the inter-
actions of several SNPs and overweight/obesity. To the
best of our knowledge, the interactions of ABCA-1, LIPG,
MTHFR, MYLIP, PCSK9, PPARD, and SCARB1 SNPs and
Table 6 Correlation between genotypes or alleles and serum lipid levels in the normal weight subjects
Lipid Genotype/allele Unstandardized coefficient Std. error Standardized coefficient t P
TC ACAT-1 rs1044925 genotype −0.131 0.053 −0.078 −2.477 0.013
LDL-R AvaII genotype −0.089 0.043 −0.062 −2.049 0.041
LDL-R AvaII allele −0.121 0.056 −0.066 −2.178 0.030
LIPC -250G>A genotype 0.156 0.045 0.106 3.443 0.001
LIPC -250G>A allele 0.204 0.057 0.111 3.593 0.000
MTHFR 677C>T genotype 0.266 0.046 0.179 5.768 0.000
MTHFR 677C>T allele 0.290 0.057 0.158 5.089 0.000
PPARD +294T>C genotype 0.101 0.048 0.066 2.104 0.036
TG LIPC -250G>A allele 0.149 0.065 0.072 2.292 0.022
MYLIP rs3757354 genotype −0.101 0.045 −0.071 −2.251 0.025
SCARB1 rs5888 genotype −0.142 0.066 −0.068 −2.157 0.031
HDL-C ACAT-1 rs1044925 genotype −0.061 0.028 −0.068 −2.177 0.030
LIPC -250G>A genotype 0.045 0.022 0.062 2.040 0.042
LIPG 584C>T genotype 0.085 0.025 0.104 3.364 0.001
LIPG 584C>T allele 0.085 0.030 0.089 2.877 0.004
MTHFR 677C>T genotype 0.105 0.024 0.134 4.361 0.000
MTHFR 677C>T allele 0.129 0.030 0.134 4.352 0.000
MYLIP rs3757354 genotype 0.054 0.021 0.082 2.609 0.009
LDL-C LIPC -250G>A genotype 0.080 0.037 0.067 2.171 0.030
LIPC -250G>A allele 0.125 0.046 0.084 2.713 0.007
MTHFR 677C>T genotype 0.146 0.036 0.126 4.016 0.000
MTHFR 677C>T allele 0.156 0.045 0.109 3.493 0.000
ApoA1 ACAT-1 rs1044925 genotype −0.047 0.018 −0.080 −2.606 0.009
LIPC -250G>A genotype 0.048 0.016 0.087 2.969 0.003
LIPC -250G>A allele 0.051 0.020 0.074 2.516 0.012
LIPG 584C>T genotype 0.040 0.016 0.075 2.467 0.014
LIPG 584C>T allele 0.049 0.019 0.079 2.608 0.009
MTHFR 677C>T genotype 0.057 0.014 0.121 3.965 0.000
MTHFR 677C>T allele 0.071 0.018 0.122 4.019 0.000
SCARB1 rs5888 genotype −0.034 0.012 −0.065 −2.742 0.006
ApoB LIPC -250G>A allele 0.033 0.013 0.078 2.498 0.013
MTHFR 677C>T genotype 0.037 0.011 0.105 3.359 0.001
MTHFR 677C>T allele 0.039 0.013 0.091 2.904 0.004
SCARB1 rs5888 allele −0.012 0.010 −0.048 −2.043 0.041
TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoA1, apolipoprotein A1; ApoB,
apolipoprotein B; ApoA1/ApoB, the ratio of apolipoprotein A1 to apolipoprotein B; ABCA-1, ATP-binding cassette transporter A1; ACAT-1, acyl-CoA:cholesterol
acyltransferase-1; LDL-R, low density lipoprotein receptor; LIPC, hepatic lipase gene; LIPG, endothelial lipase gene; MTHFR, methylenetetrahydrofolate reductase;
MYLIP, the E3 ubiquitin ligase myosin regulatory light chain-interacting protein; PCSK9, proprotein convertase subtilisin-like kexin type 9; PPARD, peroxisome
proliferator-activated receptor delta; SCARB1, Scavenger receptor class B type 1.
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been previously explored.
Study limitations
This study has several limitations. First, the levels of
education, weight, systolic blood pressure, diastolic
blood pressure, and the percentages of subjects who
consumed alcohol were higher in overweight/obese
than in normal weight subjects, whereas the percent-
ages of subjects who smoked cigarettes were lower inoverweight/obese than in normal weight subjects.
Although sex, age, education level, physical activity,
blood pressure, alcohol consumption, and cigarette
smoking have been adjusted for the statistical analysis,
we could not completely eliminate the potential effects
of these factors on serum lipid levels among different
genotypes in both groups. Second, the diet was not
adjusted for the statistical analysis. In the present study,
however, the diet in this isolated population is consistent
throughout the year and among individuals because of
Table 7 Correlation between genotypes or alleles and serum lipid levels in the overweight/obese subjects
Lipid Genotype/allele Unstandardized coefficient Std. cp error Standardized coefficient t P
TC ABCA-1 V825I all`ele 0.162 0.078 0.074 2.078 0.038
LIPG 584C>T genotype 0.228 0.073 0.109 3.122 0.002
LIPG 584C>T allele 0.251 0.084 0.105 2.993 0.003
MTHFR 677C>T genotype 0.158 0.060 0.092 2.624 0.009
MTHFR 677C>T allele 0.245 0.075 0.115 3.267 0.001
MYLIP rs3757354 genotype −0.121 0.054 −0.082 −2.264 0.024
PPARD +294T>C allele 0.222 0.083 0.096 2.666 0.008
SCARB1 rs5888 allele −0.182 0.069 −0.095 −2.633 0.009
TG MTHFR 677C>T genotype 0.272 0.106 0.090 2.556 0.011
PCSK9 E670G genotype 1.251 0.309 0.137 4.053 0.000
PPARD +294T>C allele 0.675 0.179 0.133 3.763 0.000
SCARB1 rs5888 genotype 0.232 0.099 0.084 2.337 0.020
HDL-C ABCA-1 V825I genotype −0.048 0.022 −0.077 −2.193 0.029
LIPG 584C>T genotype 0.087 0.026 0.114 3.337 0.001
LIPG 584C>T allele 0.068 0.030 0.078 2.270 0.024
MTHFR 677C>T genotype 0.097 0.023 0.146 4.122 0.000
MTHFR 677C>T allele 0.138 0.029 0.167 4.721 0.000
PCSK9 E670G genotype −0.167 0.075 −0.076 −2.234 0.026
SCARB1 rs5888 genotype −0.069 0.029 −0.084 −2.265 0.018
LDL-C ABCA-1 V825I genotype 0.134 0.040 0.119 3.308 0.001
ABCA-1 V825I allele 0.228 0.061 0.134 3.726 0.000
LIPG 584C>T genotype 0.115 0.054 0.076 2.106 0.035
LIPG 584C>T allele 0.131 0.062 0.077 2.116 0.035
ApoA1 ABCA-1 V825I allele −0.044 0.020 −0.075 −2.138 0.033
LIPG 584C>T genotype 0.036 0.018 0.071 2.038 0.042
MTHFR 677C>T genotype 0.057 0.015 0.137 3.862 0.000
MTHFR 677C>T allele 0.076 0.018 0.145 4.099 0.000
SCARB1 rs5888 genotype −0.062 0.018 −0.122 −3.523 0.000
ApoB ABCA-1 V825I genotype 0.023 0.011 0.074 2.041 0.042
ABCA-1 V825I allele 0.046 0.017 0.096 2.652 0.008
LIPC -250G>A genotype −0.034 0.012 −0.101 −2.777 0.006
MTHFR 677C>T genotype 0.028 0.013 0.077 2.147 0.032
MTHFR 677C>T allele 0.048 0.016 0.107 2.992 0.003
MYLIP rs3757354 genotype −0.026 0.012 −0.079 −2.190 0.029
SCARB1 rs5888 allele −0.052 0.015 −0.129 −3.587 0.000
ApoA1/ApoB ABCA-1 V825I genotype −0.093 0.029 −0.114 −3.168 0.002
ABCA-1 V825I allele −0.185 0.044 −0.149 −4.172 0.000
LIPC -250G>A genotype 0.132 0.036 0.132 3.698 0.000
LIPC -250G>A allele 0.114 0.048 0.085 2.361 0.018
MYLIP rs3757354 genotype 0.058 0.030 0.071 1.965 0.050
TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoA1, apolipoprotein A1; ApoB,
apolipoprotein B; ApoA1/ApoB, the ratio of apolipoprotein A1 to apolipoprotein B; ABCA-1, ATP-binding cassette transporter A1; ACAT-1, acyl-CoA:cholesterol
acyltransferase-1; LDL-R, low density lipoprotein receptor; LIPC, hepatic lipase gene; LIPG, endothelial lipase gene; MTHFR, methylenetetrahydrofolate reductase;
MYLIP, the E3 ubiquitin ligase myosin regulatory light chain-interacting protein; PCSK9, proprotein convertase subtilisin-like kexin type 9; PPARD, peroxisome
proliferator-activated receptor delta; SCARB1, Scavenger receptor class B type 1.
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http://www.cardiab.com/content/11/1/123the Bai Ku Yao’s reliance on a limited number of locally
available food items. Their staple food is corn gruel
or corn tortillas. On ordinary days, they are vegetarians
[7-9]. Finally, it is clearly established that serum lipid
levels are regulated by multiple environmental and gen-
etic factors, and their interactions [7-12]. Although we
have detected the interactions of ten SNPs and over-
weight/obesity on serum lipid levels in this study,
there are still many unmeasured environmental and gen-
etic factors and their interactions. Thus, the interactions
of gene-gene, gene-environment, and environment-
environment on serum lipid levels remain to be deter-
mined. As a matter of fact, the interrelationship of SNPs
and overweight/obesity on serum lipid levels is ex-
tremely complex, and was overlooked. For example,
obesity-related genes play a role in the central regulation
of energy balance, but some of the genes have also a role
in the adipose tissue itself [71]. Uncoupling protein 2
gene polymorphisms are associated with obesity in
some Asian populations [72]. Reduction in serum IL-18
levels across increasing numbers of +183 G-alleles
(rs 5744292) is especially apparent in patient with dia-
betes type 2 and metabolic syndrome, suggesting a bene-
ficial GG genotype in relation to cardiovascular outcome
in these patients [73]. The impact of proteasome modu-
lator 9 (PSMD9) gene within the chromosome 12q24
locus on hypercholesterolemia and contribution to
cardio- and cerebrovascular events and inflammation
may be high [74,75].
Conclusion
Several SNPs in normal weight and overweight/obese
subjects were found to be associated with serum lipid
levels in the Guangxi Bai Ku Yao population. The inter-
actions of ABCA-1, LIPC, LIPG, MTHFR, MYLIP,
PCSK9, PPARD, and SCARB1 genotypes and over-
weight/obesity on serum lipid levels were detected.
These results suggest that the differences in serum lipid
levels between normal weight and overweight/obese sub-
jects might partly result from different interactions of
several SNPs and overweight/obesity. The observed
associations and interactions between these SNPs and
serum lipid parameters in this isolated ethnic subgroup
may also be the major characteristics of these conditions
in the other ethnic groups, especially in the minorities.
However, large studies of populations with different eth-
nic origins are required to confirm these observations.
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